Freenome Multiomics Platform
AI-enabled multiomics platform for early cancer detection across multiple cancer types
Platform · OtherCompany source
Company profile
About Freenome AI
Freenome is a precision medicine company pioneering early cancer detection through blood-based screening tests. The company combines multiomics technology with artificial intelligence to detect cancer in its earliest, most treatable stages using a standard blood draw. Freenome's intelligent screening platform analyzes genomic, epigenomic, and proteomic biomarkers to detect cancer-specific signals in the bloodstream, including tumor-derived cell-free DNA (cfDNA). The company's first commercial focus is colorectal cancer (CRC) screening, addressing a critical need as CRC is the world's second deadliest cancer with over 50,000 deaths annually in the U.S. alone. Freenome's PREEMPT CRC Study, the largest clinical validation study for a blood-based CRC screening test, enrolled over 40,000 participants across more than 200 study sites and published landmark results in JAMA demonstrating clinical accuracy. The company is expanding its research into lung cancer screening through the PROACT LUNG Study and multiple cancer types through the Vallania Study. Freenome's Clinical Laboratory is CLIA-certified to perform high complexity clinical testing. The company aims to provide a less invasive, more accessible screening option to overcome barriers like discomfort and preparation that lead to low adherence rates in traditional screening methods.
Company description Freenome AI official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Freenome AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Colorectal cancer
- Lung cancer
- Multiple cancer types
Who it serves
- Clinical laboratories
- Health Systems
- Healthcare providers
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
JAMA publication of PREEMPT CRC Study results (2025), largest clinical validation study for blood-based CRC screening with 40,000+ participants. Completion of Vallania Study recruitment. Ongoing enrollment in PROACT LUNG Study.
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Lung Cancer Screening Blood Test
Blood-based test for early detection of lung cancer in development
Software · OtherCompany source
Multi-Cancer Detection Test (Vallania Study)
Next-generation blood test for detecting multiple cancer types in early stages
Software · OtherCompany source
SimpleScreen CRC
Blood-based colorectal cancer screening test using multiomics and AI/ML
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
90% survival rate when CRC detected and treated before spreading
Early stage colorectal cancer detection
Clinical validation against colonoscopy-confirmed outcomes
PREEMPT CRC Study with 40,000+ participants
PREEMPT CRC Study Participants
Validation of blood-based colorectal cancer screening test across diverse population
79.2-85% sensitivity for colorectal cancer detection and 91.5% specificity for non-advanced colorectal neoplasia across 40,000+ participants
Walgreens
Partnership to increase diversity in cancer detection research and expand access to clinical studies
Multi-year relationship established to advance clinical studies of Freenome's blood-based tests
University of Chicago
Partner for Vallania Study to enroll patients across diverse network for multi-cancer detection research
Expanded access to clinical studies across University of Chicago's diverse patient network
Renown Health
Partner for The Sanderson Study pairing real-world data with multiomics for multiple cancer detection
Partnership established with William N. Pennington Cancer Institute for multi-cancer detection study
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Freenome AI
Recent articles published on Freenome AI's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.